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ABSTRACT
Objective: The purpose of this study was to evaluate the benefits achievable by Amplicor polymer-
ase chain reaction (PCR) (F. Hoffmann-LaRoche Ltd., Basel, Switzerland) with urine specimens
in addition to PACE 2 (Gen-Probe, Inc., San Diego, California) assay with cervical swab speci-
mens in the diagnosis of Chlamydia trachomatis in women.
Methods: Cervical and urine specimens from 286 women were tested for C. trachomatis byPACE
2 and Amplicor PCR, respectively. All urine specimens were analyzed undiluted and diluted 1:10
to detect and eliminate possible PCR inhibition. A confirmatory PCR assay using major outer
membrane protein-based primers (MOMP-PCR) was used on urine specimens that were positive
by PCR from women who were negative by PACE 2 with cervical swab specimens.
Results: Of the endocervical specimens, 26 were positive by the PACE 2 assay. The PCR with
urine was positive in 21 of these patients. When the urine specimens were analyzed diluted 1:10, 4
of the 5 PCR-negative specimens from PACE 2-positive patients turned positive by the PCR.
Additionally, 4 urine specimens from PACE 2-negative women were positive by the PCR with
urine, and 3 of them could be confirmed by MOMP-PCR. Altogether, 29 women were found to be
positive for C. trachomatis by either of the two assays.
Conclusions: By using the PCR with urine specimens, an 11% increase in sensitivity could be
achieved in addition to that obtained byPACE 2 assay with cervical swab specimens. In the present
material, however, the increased sensitivity was reversed by the presence ofPCR inhibitors in 14%
of the female urine specimens. Amplicor PCR with urine specimens can undoubtedly be recom-
mended for the diagnosis of chlamydial infections in women. However, constant monitoring of the
PCR inhibition seems highly advisable to obtain full benefit of the sensitivity of the PCR. Infect.
Dis. Obstet. Gynecol. 4:276-280, 1996. (C) 1997 Wiley-Liss, Inc.
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he use of molecular biological methods in the
detection of Chlamydia trachomatis in clinical
specimens is rapidly increasing. Both an RNA hy-
bridization assay (PACE 2, Gen-Probe, Inc., San
Diego, California) and polymerase chain reaction
(PCR) assay (Roche Amplicor PCR, F. Hoffmann-
LaRoche, Basel, Switzerland) have been commer-
cially available for some time. They are based, re-
spectively, on the detection of chlamydia-specific
RNA sequence directly from the clinical specimens
with a nucleic acid probe or the amplification of a
chlamydia-specific DNA sequence by PCR prior to
the detection. Both assays have previously been
compared to cell culture for the detection of endo-
cervical chlamydial infections. The sensitivity of
PACE 2 assay has been comparable to that of cell
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culture (96.7-100%), 1,z and the Amplicor PCR has
been shown to be even more sensitive than cul-
ture.3-s In a recent study, we demonstrated an
equal sensitivity (90% vs. 88%) between Amplicor
PCR and PACE 2 performed on cervical swab
specimens obtained from a high-risk population.
6
Studies on the use of PCR with male urine
specimens have demonstrated an enhanced sensi-
tivity compared to that achieved by conventional
chlamydial cell culture with urethral swab speci-
mens."’4 Recently, PCR with urine specimens has
been applied for the diagnosis of C. trachomatis in-
fection in women. 7,s These studies have suggested
urine as a superior sample material for the detec-
tion of C. trachomatis also in women, and this find-
ing has been explained by the fact that a proportion
of female C. trachomatis infections can only be de-
tected in the urethra. In our previous study, the
presence of DNA polymerase inhibitors in 15% of
female urine specimens proved to be an unexpect-
edly frequent threat to the performance of PCR,8
but in other studies in different patient populations
the frequency of inhibitory specimens has varied
considerably, or they have not especially been
searched for.
In the present study, we aimed to determine the
benefit achievable by the Amplicor PCR with urine
specimens in addition to PACE 2 hybridization as-
say with cervical specimens. Special attention was
given to detecting the inhibitory urine specimens
in order to evaluate the actual significance of DNA
polymerase inhibitors on the sensitivity of the
PCR.
SUBJECTS AND METHODS
The study population consisted of 286 women.
Their mean age was 24 years (range 15-47 years,
median 22 years). Of them, 194 were enrolled for
symptoms suggestive of acute chlamydial infection
or with a strong suspicion of chlamydial infection
because of sexual partner’s proven or suspected
chlamydial infection. These patients were exam-
ined and treated at the outpatient clinics of Tam-
pere Community Health Centre and University
Students’ Health Care Foundation, Tampere, Fin-
land, between May and September of 1994. In ad-
dition, 92 patients who underwent routine chla-
mydial sampling prior to scheduled termination of
pregnancy were enrolled in the study. They were
examined and treated at the Department of Ob-
stetrics and Gynecology, Tampere University Hos-
pital, Tampere, Finland. Patients who had re-
ceived antimicrobial therapy in the preceding
month were excluded from the study population.
The study protocol was approved by the ethical
committees of Tampere University Hospital and
the City of Tampere. Informed consent was ob-
tained from all patients.
Endocervical swab specimens were taken and
transported by using the Gen-Probe Specimen Col-
lection Kit for Cervical or Urethral Specimens. The
specimens were stored at +4C, and analyzed
within 7 days from the sampling. Urine specimens
for Amplicor PCR were prepared as instructed, fro-
zen at-70C, and analyzed within 3 weeks from
the sampling.
The PACE 2 assay was performed according to
the manufacturer’s instructions. After RNA-DNA
hybridization, the chemiluminescence signals were
recorded by a LEADER-50 luminometer (Gen-
Probe). The cutoff level was set relative to the
mean chemiluminescence value of the three nega-
tive controls, as instructed. The probe competition
assay (Gen-Probe) was used for the verification of
specimens giving low chemiluminescence signals.
The Amplicor PCR was performed according to
the manufacturer’s instructions, and the PCR pro-
cedure was accomplished by using Perkin Elmer
Thermocycler TC 9600 (Perkin-Elmer Cetus, Nor-
walk, Connecticut). After the amplification, the
amplified nucleotide sequences were detected by
an enzyme immunoassay (EIA). The absorbances
were measured with a spectrophotometer (Multi-
scan, Labsystems Ltd., Helsinki, Finland) at a
wavelength of 450 nm. Specimens giving an absor-
bance value of >0.250 were considered positive.
Urine specimens repeatedly testing positive by
Amplicor from women who were negative by
PACE 2 in the endocervix were subjected to a con-
firmatory PCR assay using major outer membrane
protein (MOMP)-based primers as described.9 To
detect and eliminate PCR inhibition, prepared
urine specimens were further diluted 1:10 with
urine dilution buffer. The diluted specimens were
then analyzed according to the normal procedure.
A patient was considered to have a chlamydial
infection if both PACE 2 and Amplicor PCR were
positive. Additionally, if the results between PACE
2 and Amplicor PCR were discrepant specimens
that could be confirmed positive either by probe
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TABLE I. Analysis of results by Gen-Probe PACE 2 RNA hybridization with endocervical specimens and
Roche Amplicor PCR with urine specimens in the detection of Chlamydia trachomatis from 286 women
No. of Result by Amplicor Result by PACE 2
specimens PCR with urine with cervical swab Final result and conclusion
21 Positive Positive
3 Positive Negative
Positive Negative
5 Negative Positive
256 Negative Negative
Uniformly positive
Positive; the positive result by PCR was confirmed by
MOMP-PCRa; the infections were not detectable in the
cervix by PACE 2
Negative; the repeatedly low positive result by PCR could
not be confirmed by MOMP-PCR
Positive; PCR inhibitors were detected in 4 urine specimens
Uniformly negative
aConfirmatory PCR using MOMP-based primers.
competition assay or by MOMP-PCR were taken
to indicate C. trachomatis infection. The calcula-
tions of prevalence and sensitivity are based on the
total number of chlamydial infections found.
RESULTS
The results are summarized in Table 1. Of 286
cervical specimens, 26 were positive by the PACE
2 assay. The PCR with urine was positive in 21 of
these patients. Additionally, 4 urine specimens
from PACE 2-negative women were positive by
the PCR. Of the 4, 3 could be confirmed as true
positive by MOMP-PCR, whereas one urine speci-
men which was repeatedly weakly positive by PCR
(absorbance values of 0.35-0.5) remained negative
by MOMP-PCR. Two of the PCR-positive women
who were negative by PACE 2 had not received
antibiotics at their initial visit and were subjected
to second sampling about 2 weeks later. Both of
them were still positive by PCR with urine and, in
addition, both had also turned positive by PACE 2
with endocervical swabs.
When the prepared urine specimens were di-
luted 1:10 for the PCR, 4 of the 5 PCR-negative
specimens from PACE 2-positive patients turned
positive by the PCR, indicating the presence of
PCR inhibitors. In contrast, 3 urine specimens from
PACE 2-positive patients that were originally posi-
tive by the PCR turned negative when diluted,
indicating a substantial loss of sensitivity by the
additional dilution procedure.
When the total number of 29 chlamydial infec-
tions detected was regarded as the basis of calcu-
lation, the use ofPCR with female urine specimens
yielded a sensitivity of 82.8%. The sensitivity of
PACE 2 assay with endocervical specimens was
89.7%. By using both diluted and undiluted urine
specimens to eliminate PCR inhibition, the sensi-
tivity of PCR with urine could be enhanced to
96.6%.
Amplicor PCR detected C. trachomatis in the
urine specimens of 4 women that were negative by
PACE 2 with cervical specimens. Three of these 4
were confirmed positive by MOMP-PCR. The
confirmed chlamydial infections that could only be
found in urine thus represent 10% of the total num-
ber of infections found in the present study.
DISCUSSION
Earlier studies have shown that urine is inappro-
priate for chlamydial isolation.1 Various antigen
detection tests, on the other hand, have been suc-
cessfully applied for the detection of C. trachomatis
infection in male urine with a sensitivity approxi-
mating that achieved by culturing urethral swab
specimens. 11,2 The fact that similar testing of fe-
male urine did not approximate results achieved by
culturing cervical swabs was explained by assuming
that not all patients with endocervical infection had
infected urethras. 12,1- In clinical practice, urethral
sampling in females is frequently overlooked.
PCR on male urine specimens has been shown
to be a highly sensitive and specific non-invasive
technique for the diagnosis of C. trachomatis, pro-
viding an opportunity for the identification of both
asymptomatic and symptomatic infected pa-
tients),4 According to recent studies, the amplifi-
cation power of PCR appears to make possible the
same approach in females as well. 7,8
The presence of DNA polymerase inhibitors
was first described in endocervical specimens,
where the ensuing percentage of false negative re-
sults varied between 4% and 10% in different re-
ports, depending on the prevalence of chlamydial
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infection in the population studied.4,s PCR inhibi-
tors were also found in male urine although they
were first thought to occur less frequently than in
endocervical specimens, i.e., in 0-3% of true posi-
tive specimens.3,4 Wiesenfeld et al. 14 reported the
presence of PCR inhibitors in almost 10% of posi-
tive male urine specimens in a high-risk population
with 17% incidence of chlamydial infection. In a
recent study performed in a low-risk female popu-
lation, PCR inhibitors were encountered in 15% of
the resolved positive female urine specimens,
which is in complete agreement with the 14%
prevalence of PCR inhibition among the true posi-
tive specimens in the current high-risk female
population, s
Clinical specimens may contain inhibitors of the
DNA polymerase with varying frequency. The ex-
act nature of the PCR inhibitors is unknown, and
their presence cannot be predicted from the char-
acteristics of the patient or the specimen. Several
methods including dilution and repeated freezing
and thawing have been used to eliminate them but
so far, no straightforward guidelines exist for their
elimination. The present study clearly showed that
the additional dilution of the urine specimens can
be harmful for the sensitivity of the detection and
cannot be recommended for routine testing. The
testing of all specimens both undiluted and di-
luted, on the other hand, will double the reagent
and labor costs and is not tempting for routine labo-
ratories. An internal control procedure integrated as
part of the PCR assay will probably prove to be an
indispensable feature in the newly launched auto-
mated PCR applications.
In conclusion, PCR with urine specimens offers
a tempting non-invasive technique for the diagno-
sis of C. trachomatis infection in females. In this
study, it was used as an extension of the normal
routine in our laboratory employing PACE 2 assay
on cervical swab specimens. Although the current
patient material consisted of two separate groups,
the prevalence of chlamydial infection in these
groups was equal and no difference in the best
performance between these groups could be dem-
onstrated. The majority of infections found by
PACE 2 could also be found in urine by PCR.
Moreover, an 11% increase in the yield of positive
results could be achieved by the analysis of urine
by PCR, probably representing patients with chla-
mydial infection restricted to the urethra. By using
the current modification of Amplicor PCR, how-
ever, the sensitivity of detection was seriously com-
promised by the frequent presence of PCR inhibi-
tots in urine. In fact, the resulting false negative
results outnumbered the positive cases that were
only detectable by the PCR assay with urine speci-
mens. PCR with urine specimens can undoubtedly
be recommended for the diagnosis of chlamydial
infections in women. However, constant monitor-
ing of the PCR inhibition seems to be a prerequi-
site for obtaining full benefit of the sensitivity of
the PCR.
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